Traws Pharma, Inc. (TRAW)
USD 5.21
(7.64%)
USD 5.21
(7.64%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 226 Thousand | 226 Thousand | 226 Thousand | 231 Thousand | 2.18 Million | 1.22 Million |
| Cost of Revenue | 16 Thousand | 14 Thousand | 14 Thousand | - | - | - |
| Gross Profit | 210 Thousand | 212 Thousand | 212 Thousand | 231 Thousand | 2.18 Million | 1.22 Million |
| Operating Expenses | 20.5 Million | 19.85 Million | 16.72 Million | 25.22 Million | 23.86 Million | 24.45 Million |
| Selling, General and Administrative Expenses | 9.09 Million | 8.44 Million | 9.42 Million | 8.32 Million | 8.34 Million | 7.58 Million |
| Research and Development Expenses | 11.41 Million | 11.4 Million | 7.29 Million | 16.89 Million | 15.52 Million | 16.86 Million |
| Other Expenses | - | 663 Thousand | 12 Thousand | 48 Thousand | - | - |
| Cost and Expenses | 20.52 Million | 19.85 Million | 16.72 Million | 25.22 Million | 23.88 Million | 24.51 Million |
| Operating Income | -20.29 Million | -19.62 Million | -16.49 Million | -24.99 Million | -21.69 Million | -23.28 Million |
| Interest Expense | - | - | - | - | - | - |
| Income Tax Expense | - | -214.48 Thousand | -321 Thousand | 4000.00 | 10 Thousand | -124 Thousand |
| Earnings before Tax | -18.94 Million | -18.96 Million | -16.16 Million | -25.15 Million | -21.49 Million | -20.53 Million |
| Net Income | -18.94 Million | -18.96 Million | -16.16 Million | -25.15 Million | -21.5 Million | -20.57 Million |
| Earnings Per Share Basic | -0.90 | -0.91 | -0.96 | -2.17 | -22.42 | -74.83 |
| Earnings Per Share Diluted | -0.90 | -0.91 | -0.96 | -2.17 | -22.42 | -74.83 |
| Weighted Average Shares Outstanding | 20.98 Million | 20.9 Million | 16.83 Million | 11.6 Million | 958.96 Thousand | 274.93 Thousand |
| Weighted Average Shares Outstanding (Diluted) | 20.98 Million | 20.9 Million | 16.83 Million | 11.6 Million | 958.96 Thousand | 274.93 Thousand |
| Gross Margin | 0.93 | 0.94 | 0.94 | 1.00 | 1.00 | 1.00 |
| EBIT Margin | -89.74 | -86.78 | -74.35 | -107.24 | -9.93 | -18.91 |
| Profit Margin | -83.84 | -83.91 | -71.52 | -108.90 | -9.85 | -16.75 |
| EBITDA | -20.28 Million | -19.61 Million | -16.48 Million | -24.98 Million | -21.68 Million | -23.22 Million |
| Earnings Before Tax Margin | -89.81 | -86.85 | -72.99 | -108.19 | -9.94 | -18.96 |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 FY | 2023 Q4 | 2023 Q3 | 2023 Q2 |
|---|---|---|---|---|---|---|
| Revenue | 57 Thousand | 56 Thousand | 226 Thousand | 56 Thousand | 57 Thousand | 57 Thousand |
| Cost of Revenue | 4000.00 | 4000.00 | 16 Thousand | 4000.00 | 5000.00 | 4000.00 |
| Gross Profit | 53 Thousand | 52 Thousand | 210 Thousand | 52 Thousand | 52 Thousand | 53 Thousand |
| Operating Expenses | 5.93 Million | 5.26 Million | 20.52 Million | 4.51 Million | 5.14 Million | 4.66 Million |
| Selling, General and Administrative Expenses | 1.97 Million | 3.35 Million | - | 2.08 Million | 2.68 Million | 2.21 Million |
| Research and Development Expenses | 3.96 Million | 1.9 Million | - | 2.43 Million | 2.46 Million | 2.45 Million |
| Other Expenses | 205 Thousand | 229 Thousand | 1.35 Million | 278 Thousand | 350 Thousand | 360 Thousand |
| Cost and Expenses | 5.94 Million | 5.26 Million | 20.52 Million | 4.51 Million | 5.14 Million | 4.66 Million |
| Operating Income | -5.88 Million | -5.21 Million | -20.29 Million | -4.46 Million | -5.08 Million | -4.61 Million |
| Interest Expense | - | - | - | - | - | - |
| Income Tax Expense | - | -39.27 Thousand | -151.89 Thousand | -39.81 Thousand | 44.58 Thousand | -118.08 Thousand |
| Earnings before Tax | -123.14 Million | -4.98 Million | -18.94 Million | -4.18 Million | -4.73 Million | -4.25 Million |
| Net Income | -123.14 Million | -4.98 Million | -18.94 Million | -4.18 Million | -4.73 Million | -4.25 Million |
| Earnings Per Share Basic | -4.87 | -0.24 | - | -0.20 | -0.23 | -0.20 |
| Earnings Per Share Diluted | -4.87 | -0.24 | - | -0.20 | -0.23 | -0.20 |
| Weighted Average Shares Outstanding | 25.31 Million | 21.04 Million | 20.98 Million | 21 Million | 21 Million | 20.97 Million |
| Weighted Average Shares Outstanding (Diluted) | 25.31 Million | 21.04 Million | 20.98 Million | 21 Million | 21 Million | 20.97 Million |
| Gross Margin | 0.93 | 0.93 | 0.93 | 0.93 | 0.91 | 0.93 |
| EBIT Margin | -103.16 | -93.00 | - | -79.61 | -89.19 | -80.81 |
| Profit Margin | -2160.40 | -88.98 | -83.84 | -74.71 | -83.14 | -74.56 |
| EBITDA | -5.88 Million | -5.2 Million | - | -4.45 Million | -5.08 Million | -4.6 Million |
| Earnings Before Tax Margin | -103.23 | -93.07 | -89.81 | -79.68 | -89.28 | -80.88 |
YAK
ASSAMENT
RANEHOLDIN
SWEC-A
INN
BIOCON